HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.

Abstract
Circulating levels of calcium ion (Ca(2+)) are maintained within a narrow physiological range mainly by the action of parathyroid hormone (PTH) secreted from parathyroid cells. Parathyroid cells can sense small fluctuations in plasma Ca(2+) levels by virtue of a cell surface Ca(2+) receptor (CaR) that belongs to the superfamily of G-protein-coupled receptors. Calcimimetics are positive allosteric modulators that activate the CaR on parathyroid cells and thereby immediately suppress PTH secretion. Pre-clinical studies with NPS R-568, a first generation calcimimetic compound, have demonstrated that daily oral administration inhibits the elevation of plasma PTH levels and parathyroid gland hyperplasia and ameliorates impaired bone qualities in rats with chronic renal insufficiency. The results of clinical trials with cinacalcet hydrochloride, a second generation calcimimetic compound, have shown that calcimimetics possess lowering effects not only on serum PTH levels but also on serum calcium x phosphorus product levels, a hallmark of an increased risk for cardiovascular death in dialysis patients with end-stage renal disease (ESRD). Thus, calcimimetics have considerable potential as an innovative medical approach to manage secondary hyperparathyroidism associated with ESRD. Indeed, cinacalcet hydrochloride has been approved in several countries and is the first positive allosteric modulator of any G protein-coupled receptor to reach the market.
AuthorsNobuo Nagano, Edward F Nemeth
JournalJournal of pharmacological sciences (J Pharmacol Sci) Vol. 97 Issue 3 Pg. 355-60 (Mar 2005) ISSN: 1347-8613 [Print] Japan
PMID15781990 (Publication Type: Journal Article, Review)
Chemical References
  • Aniline Compounds
  • N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine
  • Naphthalenes
  • Parathyroid Hormone
  • Phenethylamines
  • Propylamines
  • Receptors, Calcium-Sensing
  • Calcium
  • Cinacalcet
Topics
  • Aniline Compounds (chemistry, pharmacology, therapeutic use)
  • Animals
  • Calcium (agonists, metabolism)
  • Cinacalcet
  • Clinical Trials as Topic
  • Drug Design
  • Drug Evaluation, Preclinical
  • Humans
  • Hyperparathyroidism, Secondary (blood, drug therapy, etiology, metabolism)
  • Kidney Failure, Chronic (complications)
  • Models, Biological
  • Molecular Structure
  • Naphthalenes (therapeutic use)
  • Parathyroid Glands (cytology, metabolism)
  • Parathyroid Hormone (blood, metabolism)
  • Phenethylamines
  • Propylamines
  • Rats
  • Receptors, Calcium-Sensing (drug effects, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: